At ESMO 2025, Dr. Andrew Hahn of MD Anderson Cancer Center shared updates on pivotal prostate cancer studies, including EMBARK, ENZARAD, PRESTO, and PSMA Addition, offering key survival data and next-generation therapy insights.
Read More
Edard Weber, MD discusses how mutations in the BRCA 1 and 2 genes and in other DNA Damage Repair genes can guide therapy decisions.
Read More
Dr. Jonas Hugosson presents updated results from the Göteborg-2 trial showing PSA plus MRI reduces overdiagnosis while maintaining detection of aggressive cancers.
Read More
Dr. Monique Roobol reports on the PRAISE-U project, showing how European risk-stratified screening pilot studies shape population-based prostate cancer care.
Read More
Dr. Rhian Gabe outlines the UK’s TRANSFORM trial, evaluating PSA thresholds, MRI, and polygenic risk scores to inform modern prostate cancer screening policy.
Read More